BARDA Funding Freeze Risks Companies Abandoning COVID Therapeutic Work
BARDA’s suspension of funding for COVID-19 therapeutics risks repeating mistakes of past pandemics as it may cause industry to pull out of the development space, experts say. Industry sources are concerned the Biden administration is focusing on funding NIH at the expense of BARDA.
You may also be interested in...
$10bn here and $6bn there on top of what’s left from earlier CARES Act gives government more options on COVID-19 medical countermeasures.
Trump’s Big Bet On COVID-19 Vaccines May Have Shortchanged Therapeutics. Should Biden Rectify The Difference?
Incoming US President may be wise to up government investment in COVID-19 therapeutics, including both research and manufacturing, experts say. Additional government funding should target a larger variety of treatment types and prioritize better study designs.
Congress wants HHS to explain why BARDA scientists were removed from leadership positions on COVID-19 vaccine contracts. It is just one of multiple examples of Democrats raising concerns that Operation Warp Speed could be hurting, not helping the COVID-19 response effort.